Immunovant, Inc. IMVT Balance Sheet Statement
| Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | ||
|---|---|---|---|---|---|---|
| $902.11M+26.4% | $994.53M+165% | $521.87M+10.3% | $598.91M+6.9% | $713.97M+12.4% | ||
| $1.13M-45.6% | $1.64M-26.1% | $1.97M+5.0% | $1.94M-19.9% | $2.08M-61.0% | ||
| $42.76M-16.4% | $46.77M+31.3% | $49.71M+52.7% | $50.92M+91.2% | $51.18M+106% | ||
| $948.82M+23.6% | $1.04B+153% | $573.55M+13.0% | $651.76M+10.6% | $767.66M+15.3% | ||
| $443K-47.5% | $531K-29.4% | $632K-5.8% | $737K+30.4% | $844K+82.7% | ||
| $7.68M+0.8% | $8.92M+17.1% | $8.78M+15.3% | $8.94M— | $7.62M— | ||
| $957.01M+23.3% | $1.05B+150% | $582.96M+13.0% | $661.44M+12.2% | $776.22M+16.5% | ||
| $7.54M-57.3% | $8.62M-56.5% | $6.92M-66.6% | $7.84M-28.9% | $17.66M+147% | ||
| $175K-35.9% | $2.41M-95.0% | $1.68M-96.3% | $1.98M-94.2% | $273K+1,720% | ||
| $104.42M+51.8% | $66.26M-3.0% | $63.25M-5.1% | $52.9M+17.5% | $68.78M+41.5% | ||
| $104.42M+51.8% | $66.26M-3.0% | $63.25M-5.1% | $52.9M+17.5% | $68.78M+41.5% | ||
| $20K+25.0% | $500M0.0% | $500M0.0% | $500M0.0% | $16K+14.3% | ||
| $2.6B+33.5% | $2.58B+74.1% | $2B+36.5% | $1.97B+35.1% | $1.95B+35.0% | ||
| -$1.75B-40.8% | -$1.6B-41.0% | -$1.49B-45.5% | -$1.36B-49.0% | -$1.24B-50.1% | ||
| $730K-50.0% | $1.2M-51.7% | $1.45M-24.1% | $1.74M-4.6% | $1.46M-23.5% | ||
| $852.59M+20.5% | $986.14M+180% | $519.71M+15.7% | $608.54M+11.7% | $707.45M+14.5% | ||
| $957.01M+23.3% | $1.05B+150% | $582.96M+13.0% | $661.44M+12.2% | $776.22M+16.5% | ||
| $7.68M+0.8% | $8.92M+17.1% | $8.78M+15.3% | $8.94M— | $7.62M— | ||
| $7.68M+0.8% | $8.92M+17.1% | $8.78M+15.3% | $8.94M— | $7.62M— | ||
| $7.68M+0.8% | $8.92M+17.1% | $8.78M+15.3% | $8.94M— | $7.62M— | ||
| —— | $57.64M— | $56.34M— | $45.06M— | $51.12M— | ||
| $175K-35.9% | —— | —— | —— | $273K+1,720% | ||
| —— | $1.27M+978% | $857K+187% | $794K+74.5% | $789K+69.7% | ||
| —— | 203.3M+38.1% | 174.5M+19.1% | 171.1M+17.0% | 170.1M+16.8% | ||
| —— | $117.2M-34.5% | $48.09M-79.5% | $73.81M-65.9% | $88.96M-69.7% | ||
| —— | 10M— | 10M— | 10M— | —— | ||
| $20K+25.0% | $20K+42.9% | $17K+21.4% | $16K+14.3% | $16K+14.3% | ||
| —— | 5M-45.1% | 6.7M-24.8% | 9.6M+13.2% | —— | ||
| —— | $0.000.0% | $0.000.0% | $0.000.0% | —— | ||
| —— | 10.6M-19.8% | 12.9M-5.2% | 14.8M+5.3% | 13M-0.5% | ||
| —— | 22.8M-2.6% | 25.4M+5.5% | 28.9M+18.1% | 23M+19.7% | ||
| —— | $15.07+25.9% | $14.23+23.1% | $12.62+9.7% | $12.00+21.8% | ||
| —— | $14.08M+25.1% | $9.52M+34.8% | $4.91M+44.3% | $15.62M+5.9% | ||
| —— | $1.27M+978% | $857K+187% | $794K+74.5% | $789K+69.7% | ||
| —— | $0— | $671K— | $862K— | $273K— | ||
| —— | $38.67M+8.7% | $42.65M+13.9% | $35.44M+25.3% | $32.62M+32.4% | ||
| —— | $1.22M— | $958K— | $1.07M— | $263K— | ||
| —— | $22.84M-2.6% | $25.43M+5.5% | $28.89M+18.1% | $23.04M+19.7% | ||
| —— | $0.000.0% | $0.000.0% | $0.000.0% | $0.000.0% | ||
| —— | $500M0.0% | $500M0.0% | $500M0.0% | $500M0.0% | ||
| —— | $203.32M+38.1% | $174.53M+19.1% | $171.07M+17.0% | $170.11M+16.8% | ||
| —— | $203.32M+38.1% | $174.53M+19.1% | $171.07M+17.0% | $170.11M+16.8% | ||
| —— | 10K0.0% | 10K0.0% | 10K0.0% | 10K0.0% | ||
| —— | $32.5M0.0% | $32.5M0.0% | $32.5M0.0% | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $2.41M+58.0% | $1.68M+59.2% | $1.98M+12.0% | $1.55M+5.6% | ||
| —— | $00.0% | $00.0% | $00.0% | —— | ||
| —— | $10.01M— | $10.01M— | $10.01M— | —— | ||
| $42.76M-16.4% | $46.77M+31.3% | $49.71M+52.7% | $50.92M+91.2% | $51.18M+106% | ||
| —— | $5.01M-45.1% | $6.75M-24.8% | $9.62M+13.2% | —— | ||
| —— | $10.59M-19.8% | $12.89M-5.2% | $14.78M+5.3% | $12.96M-0.5% | ||
| —— | $15.07+25.9% | $14.23+23.1% | $12.62+9.7% | $12+21.8% | ||
| —— | $7.63M+28.6% | $7.38M+22.0% | $8.59M+51.3% | $6.03M+188% | ||
| —— | $117.2M-34.5% | $48.09M-79.5% | $73.81M-65.9% | $88.96M-69.7% | ||
| —— | $12.32+38.1% | $11.29+28.9% | $9.97+14.6% | —— | ||
| —— | $69.04M-52.3% | $40.86M-77.0% | $65.23M-56.6% | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Immunovant, Inc.'s total assets?
- Immunovant, Inc. (IMVT) holds $957.0M in total assets, up 23.3% year over year.
- How much debt does Immunovant, Inc. have?
- Immunovant, Inc. carries $72.0K in total debt against $852.6M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does Immunovant, Inc. have?
- Immunovant, Inc. holds $902.1M in cash and equivalents.
- Can Immunovant, Inc. cover its short-term obligations?
- Its current ratio is 9.09 — current assets exceed current liabilities.
- Where does Immunovant, Inc.'s balance sheet data come from?
- Every line is extracted from Immunovant, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.